Biotechnology Swiss biotech Basilea Pharmaceutica has announced positive results of a pre-planned interim analysis in cohort 2 of the Phase II study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors), which is assessing the anti-tumor efficacy of the orally-administered fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, in patients with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer. 25 March 2021